Suda
Manufacturing · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Ratios from Marketwatch. ..., Osborne Pa...Phone Number
+61 861425555Website
www.sudapharma.comRevenue
<$5 MillionStock Symbol
SUDIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Suda
SUDA is focused on developing a radically new, first-in-class approach to the treatment of cancer using the drug anagrelide. The company is also continuing to progress its short-term insomnia treatment, ZolpiMist, for which it is expecting to hear an outcome from its TGA submission in the fourth quarter of 2020. In addition, the company is developing products in conjunction with its partners, Sanofi (EPA:SAN), Strides Pharma Global, Laboratorios Ordesa, Zelira Therapeutics (ASX:ZLD) and Cann Pharmaceutical Australia.Explore more
Suda Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Suda your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Suda had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Suda has new funding data
Check if Suda has recently received funding, and reach out quickly before it becomes old news!
Check out if Suda is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Suda
Website visits: Recent activity has been detected on your website
Suda, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Suda launches new products
Earning: See what the market has to say on Suda recently announced quarterly report
Recommended Actions
Find VP level buyers at Suda
Find 3 more new buyers
Company Profile Activity
Activity Insights
Suda is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Suda is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Suda.
Suda financials insights
Gather financial insights about Suda, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$2.7M
Suda Tech Stack
A closer look at the technologies used by Suda
See more technologies
Suda News & Media
SUDA Pharmaceuticals raises $2.7 million to develop current assets and additional technologies
The company’s cancer-fighting agent, anagrelide, recently secured a patent in Australia and a final pharmacokinetic study report acknowledged its...SUDA Pharmaceuticals appoints CEO Dr Michael Baker as new director
Dr Baker will continue to drive development opportunities for the company.Can Suda Pharmaceuticals (ASX:SUD) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Some Suda Pharmaceuticals (ASX:SUD) Shareholders Have Taken A Painful 94% Share Price Drop
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. For example, we sympathize with...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Suda
Sign Up For FreeTo access detailed company insights
SUDA is focused on developing a radically new, first-in-class approach to the treatment of cancer using the drug anagrelide. The company is also continuing to progress its short-term insomnia treatment, ZolpiMist, for which it is expecting to hear an outcome from its TGA submission in the fourth quarter of 2020. In addition, the company is developi... Read More
